ArticleJournal of virology2013
HIV-1 Vpu does not degrade interferon regulatory factor 3.
Article in Journal of virology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 35 citations in OpenAlex.
- Preservation of tetherin and CD4 counter-activities in circulating Vpu alleles despite extensive sequence variation within HIV-1 infected individuals.PLoS pathogens · 2014Trial
- Broadly neutralizing antibody epitopes on HIV-1 particles are exposed after virus interaction with host cells.Journal of virology · 2023Article
- IFI16 Targets the Transcription Factor Sp1 to Suppress HIV-1 Transcription and Latency Reactivation.Cell host & microbe · 2019Article
- HIV-1 Vpu is a potent transcriptional suppressor of NF-κB-elicited antiviral immune responses.eLife · 2019Article
- HIV-1 Infection and Type 1 Interferon: Navigating Through Uncertain Waters.AIDS research and human retroviruses · 2019Review
- HIV-1 Promotes the Degradation of Components of the Type 1 IFN JAK/STAT Pathway and Blocks Anti-viral ISG Induction.EBioMedicine · 2018Article
- Primate lentiviruses use at least three alternative strategies to suppress NF-κB-mediated immune activation.PLoS pathogens · 2017Article
- Blocking HIV-1 transmission in the female reproductive tract: from microbicide development to exploring local antiviral responses.Clinical & translational immunology · 2015Review
- HIV Vpu Interferes with NF-κB Activity but Not with Interferon Regulatory Factor 3.Journal of virology · 2015Article
- HIV Blocks Interferon Induction in Human Dendritic Cells and Macrophages by Dysregulation of TBK1.Journal of virology · 2015Article
- Innate immunity against HIV-1 infection.Nature immunology · 2015Review
- HIV-1 Nef and Vpu Interfere with L-Selectin (CD62L) Cell Surface Expression To Inhibit Adhesion and Signaling in Infected CD4+ T Lymphocytes.Journal of virology · 2015Article
- Differential regulation of NF-κB-mediated proviral and antiviral host gene expression by primate lentiviral Nef and Vpu proteins.Cell reports · 2015Article
- Microbial strategies for antagonizing Toll-like-receptor signal transduction.Current opinion in immunology · 2015Review
- Article
- HIV-1 Vpu accessory protein induces caspase-mediated cleavage of IRF3 transcription factor.The Journal of biological chemistry · 2014Article
- Viral (hepatitis C virus, hepatitis B virus, HIV) persistence and immune homeostasis.Immunology · 2014Review
- Innate DNA sensing is impaired in HIV patients and IFI16 expression correlates with chronic immune activation.Clinical and experimental immunology · 2014Article
- Innate antiviral immune signaling, viral evasion and modulation by HIV-1.Journal of molecular biology · 2014Review
- Viremic long-term nonprogressive HIV-1 infection is not associated with abnormalities in known Nef functions.Retrovirology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It has been reported that HIV-1 Vpu mediates the degradation of interferon regulatory factor 3 (IRF-3) to avoid innate immune sensing. Here, we show that Vpu does not deplete IRF-3 from transfected cell lines or HIV-1-infected primary cells. Furthermore, the Vpu-dependent suppression of beta interferon expression described in previous studies could be ascribed to inhibition of NF-κB activation. Thus, Vpu suppresses innate immune activation through inhibition of NF-κB rather than degradation of IRF-3.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.